Form 4: Amphastar Pharmaceuticals Director Michael Zasloff Increases Stake with Equity Compensation Grants

Amphastar Pharmaceuticals, Inc. Director Michael A. Zasloff reported the acquisition of 5,122 restricted stock units and 11,402 stock options as part of compensation, aligning his interests with shareholders.

Summary

• Michael A. Zasloff, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported changes in his beneficial ownership of company securities via a Form 4 filing.
• On June 2, 2025, Mr. Zasloff acquired 5,122 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These 5,122 RSUs are scheduled to vest on June 2, 2026.
• Additionally, on June 2, 2025, Mr. Zasloff acquired 11,402 stock options at a price of $0, with an exercise price of $25.38 per share.
• These 11,402 stock options are also scheduled to vest on June 2, 2026, and will expire on June 2, 2035.
• Following these transactions, Mr. Zasloff beneficially owns 29,524 shares of Common Stock and 11,402 stock options.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a compensation grant is not an open market purchase, it signifies an increase in the director's stake, aligning interests with shareholders. This is a routine and expected event for equity compensation.

Positives

• The acquisition of restricted stock units and stock options aligns the director's financial interests with those of shareholders, as his compensation is tied to the company's future stock performance.
• An increase in beneficial ownership by a director, even through compensation grants, can be viewed as a sign of continued commitment and confidence in the company's long-term prospects.

Negatives

• No specific negative points are identified in this Form 4 filing, as it primarily reports routine compensation-related equity grants rather than sales or adverse events.

Risks

• The ultimate value of the acquired restricted stock units and stock options is directly dependent on the future performance of Amphastar Pharmaceuticals' stock price.
• Stock options carry inherent risk as their profitability depends on the stock price exceeding the exercise price of $25.38 by the expiration date of June 2, 2035.

Future Outlook

The filing itself does not provide forward-looking statements or guidance regarding the company's financial performance. However, the vesting schedules for the equity grants indicate a long-term incentive structure for the director, aligning his future compensation with the company's performance over the coming years.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, a common practice across all industries for publicly traded companies. It reflects standard corporate governance mechanisms designed to align the incentives of executives and directors with the creation of shareholder value.

Stakeholder Impact

• Shareholders: The increase in director ownership through equity grants can be viewed as a positive signal, as it further aligns management's interests with shareholder value creation and long-term company performance.

Next Steps

• The 5,122 restricted stock units are expected to vest on June 2, 2026.
• The 11,402 stock options are expected to vest on June 2, 2026, and can be exercised until their expiration on June 2, 2035.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, SEC filing, insider trading, beneficial ownership, restricted stock units, RSUs, stock options, director compensation, Michael A. Zasloff, equity grants